Table 1:
Patient Characteristics
| Parenchymal (lung and liver) n=26 | Bone (n=9) | Brain (n=5) | p-value | |
|---|---|---|---|---|
| Age Median (range) | 71 (30−86) | 64 (37−78) | 66 (48−74) | 0.13 |
| PTV (cc) Median (range) | 31.3 (5.5−277.8) | 48.9 (11.5−174.1) | 0.8 (0.6−2.1) | 0.13 |
| Disease Stage | ||||
| I | 20 | 0 | 0 | |
| II | 1 | 0 | 0 | |
| IV | 5 | 9 | 5 | |
| Pack-year smoking Median (range) | 13 (0−120) | 0 (0−30) | 15 (0−40) | 0.17 |
| Dose (Gy) Median (range) | 50 (35−54) | 24 (24−27) | 21 (20−21) | <0.00001 |
| Number of fractions Median (range) | 5 (3−5) | 3 (3−3) | 1 (1−1) | <0.00001 |
| Histology (%) | 0.46 | |||
| Adenocarcinoma | 12 (46%) | 7 (78%) | 2 (40%) | |
| Squamous | 5 (19%) | 0 | 1 (20%) | |
| Sarcoma | 3 (12%) | 0 | 0 | |
| Undifferentiated/ other | 3 (12%) | 2 22%) | 2 (40%) | |
| Unbiopsied | 3 (12%) | 0 | 0 | |
| Prior systemic therapy (% Yes) | 38% | 78% | 60% | 0.11 |
| Cytoxic chemotherapy | 8 | 0 | 2 | |
| Endocrine therapy | 0 | 3 | 1 | |
| Immunotherapy | 0 | 1 | 1 | |
| Targeted Therapy | 2 | 3 | 0 |
Abbreviations: PTV = Planning Tumor Volume, Pack-years = number of pack-years of smoking cigarettes in the patient’s lifetime, Endocrine therapy = endocrine therapies for metastatic prostate cancer